Sangamo Therapeutics, Inc. Common Stock

SGMO

...

SGMO: Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Show SGMO Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of SGMO by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by SGMO's directors and management

Corporate Lobbying

Government lobbying spending instances

$20,000 Jul 20, 2022 Issue: None
$20,000 Apr 20, 2022 Issue: None
$30,000 Jan 20, 2022 Issue: None
$30,000 Oct 20, 2021 Issue: None
$27,000 Jul 21, 2021 Issue: None
$27,000 Jun 22, 2021 Issue: Medical/Disease Research/Clinical Labs

U.S. Patents

New patents grants

Patent Title: Artificial nucleases comprising engineered cleavage half-domains Aug. 15, 2023
Patent Title: Methods and compositions for treating huntington's disease Aug. 15, 2023
Patent Title: Separation and quantification of empty and full viral capsid particles Aug. 15, 2023
Patent Title: Compositions and methods for producing recombinant aav Aug. 08, 2023
Patent Title: Delivery of target specific nucleases Jul. 04, 2023
Patent Title: Genetic modification of cytokine inducible sh2-containing protein (cish) gene May. 30, 2023
Patent Title: Dna-binding proteins and uses thereof May. 30, 2023
Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene May. 23, 2023
Patent Title: Methods and compositions for gene inactivation May. 16, 2023
Patent Title: Targeted integration into the ppp1r12c locus May. 16, 2023
Patent Title: Methods and compositions for regulation of transgene expression May. 02, 2023
Patent Title: Methods and compositions for treating hemophilia Apr. 25, 2023
Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 21, 2023
Patent Title: Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder Feb. 28, 2023
Patent Title: Targeted disruption of t cell and/or hla receptors Nov. 29, 2022
Patent Title: Tau modulators and methods and compositions for delivery thereof Nov. 22, 2022
Patent Title: Methods and compositions for treatment of a genetic condition Nov. 08, 2022
Patent Title: Liver-specific constructs factor viii expression cassettes and methods of use thereof Sep. 27, 2022
Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Sep. 13, 2022
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Aug. 23, 2022
Patent Title: Engineered target specific nucleases Aug. 02, 2022
Patent Title: Targeted disruption of the t cell receptor Jun. 07, 2022
Patent Title: Methods and compositions for targeted cleavage and recombination Apr. 26, 2022
Patent Title: Targeted disruption of the mhc cell receptor Mar. 29, 2022
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Mar. 22, 2022
Patent Title: T cell modifying compounds and uses thereof Feb. 01, 2022
Patent Title: Methods and compositions for modulating pd1 Feb. 01, 2022
Patent Title: Methods and compositions for the treatment of fabry disease Jan. 11, 2022
Patent Title: Methods and compositions for targeted single-stranded cleavage and targeted integration Oct. 19, 2021
Patent Title: Artifical nucleases comprising engineered cleavage half-domains Oct. 05, 2021
Patent Title: Htt repressors and uses thereof Sep. 21, 2021
Patent Title: Methods and compositions for treating huntington's disease Sep. 07, 2021
Patent Title: Compositions for linking dna-binding domains and cleavage domains Jun. 22, 2021
Patent Title: Method for the treatment of lysosomal storage diseases Jun. 22, 2021
Patent Title: Gene correction of scid-related genes in hematopoietic stem and progenitor cells Jun. 01, 2021
Patent Title: Methods and compositions for regulation of transgene expression Apr. 13, 2021
Patent Title: Engineered target specific nucleases Apr. 13, 2021
Patent Title: Methods and compositions for genome engineering Apr. 06, 2021
Patent Title: Modulation of liver genes Mar. 30, 2021
Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Feb. 16, 2021
Patent Title: Isolated human cell with an inactivated glucocorticoid receptor gene Feb. 02, 2021
Patent Title: Methods and compositions for enhancing targeted transgene integration Jan. 12, 2021
Patent Title: Modulation of stem cells using zinc finger proteins Jan. 12, 2021
Patent Title: Methods and compositions for delivery of biologics Jan. 05, 2021
Patent Title: Methods and compositions for treating huntington's disease Dec. 08, 2020
Patent Title: Methods and compositions for modification of a hla locus Dec. 08, 2020
Patent Title: Method of inactivating the ipk1 gene in corn Nov. 10, 2020
Patent Title: Liver-specific constructs and methods of use thereof Nov. 10, 2020
Patent Title: Compositions for linking dna-binding domains and cleavage domains Nov. 03, 2020
Patent Title: Nuclease-mediated regulation of gene expression Oct. 20, 2020

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on SGMO's company Twitter account

WallStreetBets

Number of mentions of SGMO in WallStreetBets Daily Discussion

SGMO News

Recent insights relating to SGMO

CNBC Recommendations

Recent picks made for SGMO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in SGMO

Corporate Flights

Flights by private jets registered to SGMO